Incyte Corporation (NASDAQ: INCY) stock closed at 82.58 per share at the end of the most recent trading day (a -5.66% change compared to the prior day closing price) with a volume of 2.68M shares and market capitalization of 18.16B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1773 people. Incyte Corporation CEO is Herve Hoppenot.

The one-year performance of Incyte Corporation stock is -8.89%, while year-to-date (YTD) performance is -5.06%. INCY stock has a five-year performance of 2.7%. Its 52-week range is between 75.52 and 110.36, which gives INCY stock a 52-week price range ratio of 20.26%

Incyte Corporation currently has a PE ratio of 38.20, a price-to-book (PB) ratio of 6.72, a price-to-sale (PS) ratio of 6.93, a price to cashflow ratio of 23.90, a PEG ratio of 2.32, a ROA of 14.69%, a ROC of 20.12% and a ROE of 20.20%. The company’s profit margin is 18.65%, its EBITDA margin is 22.00%, and its revenue ttm is $2.70 Billion , which makes it $12.29 revenue per share.

Of the last four earnings reports from Incyte Corporation, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.56 for the next earnings report. Incyte Corporation’s next earnings report date is 03rd Aug 2021.

The consensus rating of Wall Street analysts for Incyte Corporation is Moderate Buy (2.07), with a target price of $97.1, which is +17.58% compared to the current price. The earnings rating for Incyte Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Incyte Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Incyte Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 12.84, ATR14 : 2.30, CCI20 : -35.45, Chaikin Money Flow : -0.03, MACD : 0.55, Money Flow Index : 46.09, ROC : -0.12, RSI : 46.57, STOCH (14,3) : 23.07, STOCH RSI : 0.00, UO : 50.48, Williams %R : -76.93), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Incyte Corporation in the last 12-months were: Barry P. Flannelly (Option Excercise at a value of $1 538 374), Barry P. Flannelly (Sold 30 325 shares of value $2 804 405 ), Dashyant Dhanak (Option Excercise at a value of $535 463), Dashyant Dhanak (Sold 7 348 shares of value $671 766 ), Herve Hoppenot (Buy at a value of $1 000 007), Herve Hoppenot (Option Excercise at a value of $19 716 404), Herve Hoppenot (Sold 269 313 shares of value $29 624 430 ), Jean-Jacques Bienaime (Sold 798 shares of value $66 234 ), Jonathan Elliott Dickinson (Sold 9 000 shares of value $947 790 ), Maria E Pasquale (Option Excercise at a value of $418 789), Maria E Pasquale (Sold 5 039 shares of value $476 675 ), Maria E. Pasquale (Option Excercise at a value of $427 090), Maria E. Pasquale (Sold 5 039 shares of value $476 675 ), Michael James Morrissey (Sold 20 000 shares of value $1 621 600 ), Paul Trower (Option Excercise at a value of $448 171), Paul Trower (Sold 6 943 shares of value $763 730 ), Steven H. Stein (Option Excercise at a value of $3 046 166), Steven H. Stein (Sold 45 017 shares of value $4 830 757 ), Vijay K. Iyengar (Option Excercise at a value of $873 009), Vijay K. Iyengar (Sold 16 577 shares of value $1 720 878 ), Wendy L. Dixon (Option Excercise at a value of $379 400), Wendy L. Dixon (Sold 20 000 shares of value $1 890 200 ), Wenqing Yao (Option Excercise at a value of $2 645 805), Wenqing Yao (Sold 38 098 shares of value $3 930 968 )